Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775434 · ClinicalTrials.gov registry record · Phase 1
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis and Eczema, sponsored by AOBiome.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 6
- Study locations
NCT03775434: Completed Phase 1 study of Atopic Dermatitis and Eczema, sponsored by AOBiome.
NCT03775434 is a Phase 1 study of Atopic Dermatitis and Eczema that has completed, run by AOBiome. The registered enrollment target is 28 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03775434, a Phase 1 study of Atopic Dermatitis and Eczema, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 6
- Study locations
Study Summary
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b
Primary Outcome
Safety and tolerability endpoints will consist of all adverse events reporting from Baseline to Day 28.
Conditions Studied
Interventions
- DRUG Experimental: B244
Study Locations (6)
Arkansas
- Dermatology Trial Associates - Bryant
California
- L.A. Universal Research Center, Inc. - Los Angeles
Indiana
- The Indiana Clinical Trials Center - Plainfield
Minnesota
- Minnesota Clinical Study Center - Fridley
Nebraska
- Skin Specialists, PC - Omaha
Virginia
- Virginia Clinical Research, INC - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 1 |
What the finished NCT03775434 record still lists
NCT03775434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Experimental: B244 is the first listed.
NCT03775434 lists 6 locations in 6 states (Arkansas, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT03775434 about?
NCT03775434 is a clinical study titled "A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis". An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b
What is the current status of trial NCT03775434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-12-07. Estimated completion is 2019-06-10.
What conditions does trial NCT03775434 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT03775434?
The interventions under investigation include: Experimental: B244 (DRUG).
Who is sponsoring clinical trial NCT03775434?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03775434 being conducted?
This trial has 6 study locations across Arkansas, California, Indiana, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03775434's enrollment target sits among peer trials
28 127th of 150 higher than 23 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI